Inhaled Technosphere Insulin Compared With Injected Prandial Insulin in Type 1 Diabetes: A Randomized 24-Week Trial
The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To compare the efficacy and safety of Technosphere insulin (TI) and insulin aspart in patients with type 1 diabetes. RESEARCH DESIGN AND METHODS: This open-label noninferiority trial compared the change in HbA1c from baseline to week 24 of prandial TI (n = 174) with that of subcutaneous aspart (n = 171), both with basal insulin, in patients with type 1 diabetes and HbA1c 7.5–10.0% (56.8–86.0 mmol/mol). RESULTS: Mean change in HbA1c in TI patients (–0.21% [–2.3 mmol/mol]) from baseline (7.94% [63.3 mmol/mol]) was noninferior to that in aspart patients (–0.40% [–4.4 mmol/mol]) from baseline (7.92% [63.1 mmol/mol]). The between-group difference was 0.19% (2.1 mmol/mol) (95% CI 0.02–0.36), satisfying the noninferiority margin of 0.4%. However, more aspart patients achieved HbA1c <7.0% (53.0 mmol/mol) (30.7% vs. 18.3%). TI patients had a small weight loss (–0.4 kg) compared with a gain (+0.9 kg) for aspart patients (P = 0.0102). TI patients had a lower hypoglycemia event rate than aspart patients (9.8 vs. 14.0 events/patient-month, P < 0.0001). Cough (generally mild) was the most frequent adverse event (31.6% with TI, 2.3% with aspart), leading to discontinuation in 5.7% of patients. Treatment group difference for mean change from baseline in forced expiratory volume in 1 s was small (40 mL) and disappeared upon TI discontinuation. CONCLUSIONS: In patients with type 1 diabetes receiving basal insulin, HbA1c reduction with TI was noninferior to that of aspart, with less hypoglycemia and less weight gain but increased incidence of cough.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“the use of rapid-acting analogs has resulted in less hypoglycemia, with small reductions in A1C compared to using regular human insulin, including MDI using NPH as basal insulin.1151–1153”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [1153]
In the citing paper
“Results from comparative effectiveness meta-analyses suggest that each new class of oral noninsulin agents when added to metformin generally lowers A1C by approximately 0.7-1.0%(8-11 mmol/mol).”
From 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2025 (2025) · cites this paper as [10]
Citations
Cites
Standards of medical care in diabetes—2014
American Diabetes Association (2014) · Diabetes Care · doi:10.2337/dc14-s014 · Cited by 4,572
Spirometric Reference Values from a Sample of the General U.S. Population
HANKINSON, J. L., ODENCRANTZ, J. R., & FEDAN, K. B. (1999) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.159.1.9712108 · Cited by 4,206 · cited 1×
“criteria were nonsmoking for the preceding 6 months, BMI #38 kg/m(2), forced expiratory volume in 1 s (FEV1) and forced vital capacity (FVC) $70% predicted (11), and stable insulin dose (,2 IU/kg/day) with fasting plasma glucose (FPG),220mg/dL for 3months before screening.”
BackgroundThe prevention and treatment of missing data in clinical trials
Little, R. J., D'Agostino, R., Cohen, M. L., Dickersin, K., Emerson, S. S., Farrar, J. T., Frangakis, C., Hogan, J. W., Molenberghs, G., Murphy, S. A., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmsr1203730 · Cited by 1,884
Morris, A. D., Boyle, D. I., McMahon, A. D., Greene, S. A., MacDonald, T. M., & Newton, R. W. (1997) · The Lancet · doi:10.1016/s0140-6736(97)06234-x · Cited by 507
Correlates of Insulin Injection Omission
Peyrot, M., Rubin, R. R., Kruger, D. F., & Travis, L. B. (2010) · Diabetes Care · doi:10.2337/dc09-1348 · Cited by 407 · cited 1×
“Lack of compliance with insulin therapy is a frequent problem in patients with type 1 diabetes due to pain and embarrassment associated with insulin injections (5).”
BackgroundGlycemic Exposure Is Associated With Reduced Pulmonary Function in Type 2 Diabetes
Davis, W. A., Knuiman, M., Kendall, P., Grange, V., & Davis, T. M. E. (2004) · Diabetes Care · doi:10.2337/diacare.27.3.752 · Cited by 323 · cited 1×
“There is some evidence that the decline in pulmonary function in patients with diabetes is greater than that of the general population (22).”
BackgroundMMRM vs. LOCF: A Comprehensive Comparison Based on Simulation Study and 25 NDA Datasets
Siddiqui, O., Hung, H. M. J., & O'Neill, R. (2009) · Journal of Biopharmaceutical Statistics · doi:10.1080/10543400802609797 · Cited by 301 · cited 1×
“First, the analysis method (MMRM) is a preferred model for addressing missing data (23,24).”
MethodUse of Inhaled Insulin in a Basal/Bolus Insulin Regimen in Type 1 Diabetic Subjects
Skyler, J. S., Weinstock, R. S., Raskin, P., Yale, J.-F., Barrett, E., Gerich, J. E., Gerstein, H. C., & the Inhaled Insulin Phase III Type 1 Diabetes Study Group (2005) · Diabetes Care · doi:10.2337/diacare.28.7.1630 · Cited by 269
Hypoglycemia in Type 1 Diabetes Mellitus
Cryer, P. E. (2010) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2010.05.003 · Cited by 205
Rosenstock, J., Lorber, D. L., Gnudi, L., Howard, C. P., Bilheimer, D. W., Chang, P.-C., Petrucci, R., Boss, A., & Richardson, P. C. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60632-0 · Cited by 122
Self-citation
Cited by
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2022
American Diabetes Association Professional Practice Committee (2022) · Diabetes Care · doi:10.2337/dc22-s009 · Cited by 1,555
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2021
American Diabetes Association (2021) · Diabetes Care · doi:10.2337/dc21-s009 · Cited by 972
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2020
American Diabetes Association (2020) · Diabetes Care · doi:10.2337/dc20-s009 · Cited by 914
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2023
ElSayed, N. A., Aleppo, G., Aroda, V. R., Bannuru, R. R., Brown, F. M., Bruemmer, D., Collins, B. S., Hilliard, M. E., Isaacs, D., Johnson, E. L., et al. (2023) · Diabetes Care · doi:10.2337/dc23-s009 · Cited by 851
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2019
American Diabetes Association (2019) · Diabetes Care · doi:10.2337/dc19-s009 · Cited by 739
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2025
American Diabetes Association Professional Practice Committee, ElSayed, N. A., McCoy, R. G., Aleppo, G., Bajaj, M., Balapattabi, K., Beverly, E. A., Briggs Early, K., Bruemmer, D., Echouffo-Tcheugui, J. B., et al. (2025) · Diabetes Care · doi:10.2337/dc25-s009 · Cited by 728
8. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2018
American Diabetes Association (2018) · Diabetes Care · doi:10.2337/dc18-s008 · Cited by 699
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2024
American Diabetes Association Professional Practice Committee, ElSayed, N. A., Aleppo, G., Bannuru, R. R., Bruemmer, D., Collins, B. S., Ekhlaspour, L., Gaglia, J. L., Hilliard, M. E., Johnson, E. L., et al. (2024) · Diabetes Care · doi:10.2337/dc24-s009 · Cited by 662
Overcoming barriers to patient adherence: the case for developing innovative drug delivery systems
Baryakova, T. H., Pogostin, B. H., Langer, R., & McHugh, K. J. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-023-00670-0 · Cited by 492
Blonde, L., Umpierrez, G. E., Reddy, S. S., McGill, J. B., Berga, S. L., Bush, M., Chandrasekaran, S., DeFronzo, R. A., Einhorn, D., Galindo, R. J., et al. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.08.002 · Cited by 507
Self-citation8. Pharmacologic Approaches to Glycemic Treatment
American Diabetes Association (2017) · Diabetes Care · doi:10.2337/dc17-s011 · Cited by 458
9. pharmacologic approaches to glycemic treatment: standards of care in diabetes—2026
American Diabetes Association Professional Practice Committee for Diabetes*, Bajaj, M., McCoy, R. G., Balapattabi, K., Bannuru, R. R., Bellini, N. J., Bennett, A. K., Beverly, E. A., Briggs Early, K., ChallaSivaKanaka, S., et al. (2026) · Diabetes Care · doi:10.2337/dc26-s009 · Cited by 263
Danne, T., Phillip, M., Buckingham, B. A., Jarosz-Chobot, P., Saboo, B., Urakami, T., Battelino, T., Hanas, R., & Codner, E. (2018) · Pediatric Diabetes · doi:10.1111/pedi.12718 · Cited by 225
“An inhaled form of human insulin (Afrezza) has been approved as prandial insulin for adults in the United States.24”
BackgroundInsulin Therapy in Adults with Type 1 Diabetes Mellitus: a Narrative Review
Janež, A., Guja, C., Mitrakou, A., Lalic, N., Tankova, T., Czupryniak, L., Tabák, A. G., Prazny, M., Martinka, E., & Smircic-Duvnjak, L. (2020) · Diabetes Therapy · doi:10.1007/s13300-019-00743-7 · Cited by 177
One hundred years of insulin therapy
Mathieu, C., Martens, P.-J., & Vangoitsenhoven, R. (2021) · Nature Reviews Endocrinology · doi:10.1038/s41574-021-00542-w · Cited by 164
Kumar, M., Hilles, A. R., Almurisi, S. H., Bhatia, A., & Mahmood, S. (2023) · JCIS Open · doi:10.1016/j.jciso.2023.100095 · Cited by 138
Wearable, Sensing-Controlled, Ultrasound-Based Microneedle Smart System for Diabetes Management
Luo, X., Yu, Q., Yang, L., & Cui, Y. (2023) · ACS Sensors · doi:10.1021/acssensors.2c02863 · Cited by 116
Doyle-Delgado, K., Chamberlain, J. J., Shubrook, J. H., Skolnik, N., & Trujillo, J. (2020) · Annals of Internal Medicine · doi:10.7326/m20-2470 · Cited by 111
Pharmacokinetic and Pharmacodynamic Properties of a Novel Inhaled Insulin
Heinemann, L., Baughman, R., Boss, A., & Hompesch, M. (2017) · Journal of Diabetes Science and Technology · doi:10.1177/1932296816658055 · Cited by 84
“1% from randomization to Week 12, and TI dose increased by 43%.(31) In the same study, a small increase in basal insulin requirement was also seen, as would be expected when transitioning to an insulin with a shorter duration of action.”
BackgroundMethodResultInfluentialCommentary: Why Was Inhaled Insulin a Failure in the Market?
Oleck, J., Kassam, S., & Goldman, J. D. (2016) · Diabetes Spectrum · doi:10.2337/diaspect.29.3.180 · Cited by 84
“The AFFINITY-1 study concluded that, in patients with type 1 diabetes receiving basal insulin, A1C reduction with Afrezza was noninferior to insulin aspart and significantly fewer patients experienced hypoglycemia (6).”
Backgroundda Silva, R. Y. P., de Menezes, D. L. B., Oliveira, V. D. S., Converti, A., & de Lima, Á. A. N. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24065441 · Cited by 81
“AfrezzaTM, or Technosphere Insulin (TI), is an inhalation powder formulation that came to the market as an alternative to injectable insulin [96,97].”
BackgroundAkturk, H. K., Snell-Bergeon, J. K., Rewers, A., Klaff, L. J., Bode, B. W., Peters, A. L., Bailey, T. S., & Garg, S. K. (2018) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2018.0200 · Cited by 70
“An initial study using TI demonstrated noninferiority in glucose control when compared with insulin aspart in patients with T1DM using MDI.(13) This registration study also documented fewer hypoglycemic events with lesser weight gain in subjects with T1DM.”
ResultSelf-citationViceconti, M., Cobelli, C., Haddad, T., Himes, A., Kovatchev, B., & Palmer, M. (2017) · Proceedings of the Institution of Mechanical Engineers, Part H: Journal of Engineering in Medicine · doi:10.1177/0954411917702931 · Cited by 64
“prandial insulin Aspart (Novolog ).(100) However, because of the fast onset and short duration of action, the dosing regimen of TI in this study may have been suboptimal.”
BackgroundChamberlain, J. J., Kalyani, R. R., Leal, S., Rhinehart, A. S., Shubrook, J. H., Skolnik, N., & Herman, W. H. (2017) · Annals of Internal Medicine · doi:10.7326/m17-1259 · Cited by 61
Structural principles of insulin formulation and analog design: A century of innovation
Jarosinski, M. A., Dhayalan, B., Chen, Y., Chatterjee, D., Varas, N., & Weiss, M. A. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2021.101325 · Cited by 58
Emerging Diabetes Technologies: Continuous Glucose Monitors/Artificial Pancreases
ALMURASHI, A. M., Rodriguez, E., & Garg, S. K. (2023) · Journal of the Indian Institute of Science · doi:10.1007/s41745-022-00348-3 · Cited by 66
Advances in Nanomedicine for Precision Insulin Delivery
Caturano, A., Nilo, R., Nilo, D., Russo, V., Santonastaso, E., Galiero, R., Rinaldi, L., Monda, M., Sardu, C., Marfella, R., et al. (2024) · Pharmaceuticals · doi:10.3390/ph17070945 · Cited by 56
AFREZZA® (insulin human) Inhalation Powder: A Review in Diabetes Mellitus
Kim, E., & Plosker, G. L. (2015) · Drugs · doi:10.1007/s40265-015-0472-0 · Cited by 50
“Patients were also excluded if they had experienced C2 severe episodes of hypoglycaemia in the 3 [17] or 6 months [16] leading up to screening.”
InfluentialRethinking the Viability and Utility of Inhaled Insulin in Clinical Practice
Heinemann, L., & Parkin, C. G. (2018) · Journal of Diabetes Research · doi:10.1155/2018/4568903 · Cited by 48
“Needle phobia in a subgroup of patients with diabetes, which often goes unrecognized or unreported, contributes to patient inertia and manifests as resistance to starting insulin injections even as T2D progresses from insulin resistance to total insulin deficiency [23, 24].”
BackgroundMethodInfluentialNew Hope for Treating Intervertebral Disc Degeneration: Microsphere-Based Delivery System
Guo, T., Zhang, X., Hu, Y., Lin, M., Zhang, R., Chen, X., Yu, D., Yao, X., Wang, P., & Zhou, H. (2022) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2022.933901 · Cited by 49
Nkonge, K. M., Nkonge, D. K., & Nkonge, T. N. (2023) · Diabetes Therapy · doi:10.1007/s13300-023-01468-4 · Cited by 42
Insulinoterapia no diabetes mellitus tipo 1 (DM1)
Júnior, W. S. D. S., Gabbay, M. A. L., Lamounier, R. N., & Bertoluci, M. C. (2022) · Conectando Pessoas eBooks · doi:10.29327/557753.2022-5 · Cited by 59
Visentin, R., Giegerich, C., Jäger, R., Dahmen, R., Boss, A., Grant, M., Dalla Man, C., Cobelli, C., & Klabunde, T. (2016) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2016.0128 · Cited by 36
McGill, J. B., Peters, A., Buse, J. B., Steiner, S., Tran, T., Pompilio, F. M., & Kendall, D. M. (2020) · Clinical Drug Investigation · doi:10.1007/s40261-020-00958-8 · Cited by 35
Self-citationPossible Ways to Improve Postprandial Glucose Control in Type 1 Diabetes
Aktürk, H. K., Rewers, A. H., Joseph, H., Schneider, N., & Garg, S. K. (2018) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2018.0114 · Cited by 38
Effect of Afrezza on Glucose Dynamics During HCL Treatment
Galderisi, A., Cohen, N., Calhoun, P., Kraemer, K., Breton, M., Weinzimer, S., & Cengiz, E. (2020) · Diabetes Care · doi:10.2337/dc20-0091 · Cited by 32
Excipient-free pulmonary insulin dry powder: Pharmacokinetic and pharmacodynamics profiles in rats
Quarta, E., Chierici, V., Flammini, L., Tognolini, M., Barocelli, E., Cantoni, A. M., Dujovny, G., Ecenarro, S., Sonvico, F., Colombo, G., et al. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.04.015 · Cited by 32
LEVIN, P. A., Hoogwerf, B. J., Snell‐Bergeon, J. K., Vigers, T., Pyle, L. L., & Bromberger, L. A. (2020) · Endocrine Practice · doi:10.1016/j.eprac.2020.10.004 · Cited by 32
Seaquist, E. R., Blonde, L., McGill, J. B., Heller, S. R., Kendall, D. M., Bumpass, J. B., Pompilio, F. M., & Grant, M. L. (2020) · Diabetic Medicine · doi:10.1111/dme.14202 · Cited by 30
Self-citationGrant, M., Heise, T., & Baughman, R. (2022) · Clinical Pharmacokinetics · doi:10.1007/s40262-021-01084-0 · Cited by 30
Hirsch, I. B., Beck, R. W., Marak, M. C., Kudva, Y. C., Aktürk, H. K., Bhargava, A., Codorniz, K., Diner, J., Aleppo, G., Blevins, T., et al. (2024) · Diabetes Care · doi:10.2337/dc24-1832 · Cited by 28
Self-citationInhaled Insulin: A Clinical and Historical Review
Chan, J., & Cheng-Lai, A. (2017) · Cardiology in Review · doi:10.1097/crd.0000000000000143 · Cited by 32
Pharmacologic treatment options for type 1 diabetes: what’s new?
Nally, L. M., Sherr, J. L., Name, M. A. V., Patel, A., & Tamborlane, W. V. (2019) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2019.1597705 · Cited by 26
Results of a 24-week trial of technosphere insulin versus insulin aspart in type 2 diabetes
Hoogwerf, B. J., Pantalone, K. M., Basina, M., Jones, M. C., Grant, M., & Kendall, D. M. (2021) · Endocrine Practice · doi:10.1016/j.eprac.2020.11.002 · Cited by 22
Technosphere insulin: inhaled prandial insulin
Setji, T. L., Hong, B. D., & Feinglos, M. N. (2015) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2016.1121230 · Cited by 22
Recommendations for Initiating Use of Afrezza Inhaled Insulin in Individuals with Type 1 Diabetes
Pettus, J., Cavaiola, T. S., & Edelman, S. V. (2018) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2017.0463 · Cited by 20
Place of technosphere inhaled insulin in treatment of diabetes
Mikhail, N. E. (2016) · World Journal of Diabetes · doi:10.4239/wjd.v7.i20.599 · Cited by 18
Making Insulin Accessible: Does Inhaled Insulin Fill an Unmet Need?
McGill, J. B., Ahn, D. T., Edelman, S. V., Kilpatrick, C. R., & Cavaiola, T. S. (2016) · Advances in Therapy · doi:10.1007/s12325-016-0370-1 · Cited by 18
Self-citationLessons for modern insulin development
Herring, R. A., & Russell-Jones, D. L. (2018) · Diabetic Medicine · doi:10.1111/dme.13692 · Cited by 17
Tan, P. K., Kuppusamy, U. R., Chua, K. H., & Arumugam, B. (2022) · Current Drug Delivery · doi:10.2174/1567201820666221102094433 · Cited by 17
Beck, R. W., Bailey, R. J., Klein, K. R., Aleppo, G., Levy, C. J., Diner, J., Jacobson, C., Levister, C. M., Calhoun, P. M., Ruedy, K. J., et al. (2025) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2024.0582 · Cited by 14
Self-citationSegal, A. R., Vootla, T., & Beaser, R. S. (2016) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2016.06.009 · Cited by 14
Khan, A. B., Ahmad, A., Ahmad, S., Gul, M., Iqbal, F., Ullah, H., Laiba, S., & Orakzai, U. K. (2022) · Cureus · doi:10.7759/cureus.23731 · Cited by 12
“DOI 10.7759/cureus.23731 6 of 10 FIGURE 4: Forest plot showing effect size of Inhaled Insulin vs Control in Change in weight FIGURE 5: Forest plot showing effect size of Inhaled Insulin vs Control in Fasting Blood Glucose HbA1c: Out of thirteen studies, twelve studies were selected to analyze HbA1c [13-17, 19-25].”
BackgroundInfluentialBeck, R. W., Bailey, R. J., Aktürk, H. K., Rizvi, S. R., Kudva, Y. C., Blevins, T., Church, M. M., Manessis, A., Calhoun, P. M., Ruedy, K. J., et al. (2025) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2024.0581 · Cited by 11
Self-citationHaller, M. J., Kanapka, L. G., Monzavi, R., Mouse, T. J., Prakasam, G., Dewan, A. K., DiMeglio, L. A., Laffel, L. M., Willi, S. M., Tansey, M., et al. (2025) · Diabetes Care · doi:10.2337/dc25-1994 · Cited by 11
The Need for Faster Insulin: Problem Solved?
Muchmore, D. B. (2016) · Journal of Diabetes Science and Technology · doi:10.1177/1932296816677577 · Cited by 10
“This novel profile has the attractive property of allowing insulin dosing to occur right at the time of meal initiation (rather than having to wait 15 minutes or more between RAI dosing and meal start) while also reducing the risk of late postmeal hypoglycemia.(6) On the negative side, however, this “ultra-short” dura…”
BackgroundAng, K. H., & Sherr, J. L. (2017) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2017.1360862 · Cited by 11
“Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus.”
BackgroundInsulin’s Role in Diabetes Management: After 90 Years, Still Considered the Essential “Black Dress”
Cefalu, W. T., Rosenstock, J., LeRoith, D., & Riddle, M. C. (2015) · Diabetes Care · doi:10.2337/dci15-0023 · Cited by 10
Advances in Care for Insulin-Requiring Patients Without Closed Loop
Lal, R., Buckingham, B. A., & Maahs, D. M. (2018) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2018.0084 · Cited by 10
Living with Insulin: The story of insulin from people with diabetes
Bartolo, P. D., & Eckel, R. H. (2021) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.108857 · Cited by 9
Santos, V. K. J. D., Prado, M. L. D. L., Silva, G. H. M. C., Aragão, I. C. S., Aragão, F. M. S., dos Santos, V. H. S., Hespanhol, L. C., de Menezes, V. L., Reis, F. P., & Aragão, J. A. (2025) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2025.109108 · Cited by 8
LEVIN, P. A., Heinemann, L., Boss, A., & Rosenblit, P. D. (2016) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2016-000228 · Cited by 8
A Population Dose-Response Model for Inhaled Technosphere Insulin Administered to Healthy Subjects
Rüppel, D., Dahmen, R., Boss, A., Jäger, R., GRANT, M. L., Baughman, R., & Klabunde, T. (2017) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12189 · Cited by 8
Physiological models for artificial pancreas development
VISENTIN, R., Schiavon, M., Basu, R., Basu, A., Man, C. D., & Cobelli, C. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-815655-1.00015-6 · Cited by 10
A novel option for prandial insulin therapy: inhaled insulin
Dailey, G., Ahmad, A., Polsky, S., & Shah, V. N. (2016) · Postgraduate medicine · doi:10.1080/00325481.2016.1229555 · Cited by 6
“Inhaled TI plus basal insulin was compared with insulin aspart plus basal insulin in patients with T1D in a 24-week study with the primary efficacy endpoint of change in A1C from baseline to week 24 (Table 2) [51].”
MethodTechnosphere Inhaled Insulin: Is Faster Better?
Leahy, J. L. (2015) · Diabetes Care · doi:10.2337/dci15-0002 · Cited by 7
Jacobson, C., Kaiserman, K. B., Ulloa, J., Pleitez, J., Sylvan, J., RINKER, J. K., Codorniz, K., Lee, S., Vakhshoori, M., Moreno, P. L., et al. (2025) · Diabetes Therapy · doi:10.1007/s13300-025-01760-5 · Cited by 6
Cowart, K., Everich, H., Flores, F., Harris, M., Randall, D., Sammartano, L., & Carris, N. W. (2026) · Diabetes Technology & Therapeutics · doi:10.1177/15209156251387102 · Cited by 5
Pharmacological aspects of closed loop insulin delivery for type 1 diabetes
Uduku, C. N., & Oliver, N. S. (2017) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2017.07.006 · Cited by 5
Sánchez, E., Mizab, C., Sauret, A., Barbé, F., Martí, R., López‐Cano, C., Hernández, M., Gutiérrez-Carrasquilla, L., Carmona, P., González, J., et al. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9051249 · Cited by 5
“In this way, a decline equal or higher than≥15% occurred in 6% of Technosphere insulin treated subjects compared to 3% of comparator-treated subjects [13,14].”
Villar‐Taibo, R., Sanz-Pastor, A. G., Fernández-Rubio, E., Galindo, D. E. B., Simó-Servat, A., & Ampudia‐Blasco, F. J. (2024) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2023.0524 · Cited by 4
Insulin Analogs and the Mode of Insulin Delivery: Recent Advances and Challenges
Bhagi, M., Kaur, J., Dhar, A., & Bhat, A. (2024) · Current Pharmaceutical Biotechnology · doi:10.2174/0113892010287216240324050651 · Cited by 4
Si l'ère des insulines semi-synthétiques et biosynthétiques nous était contée
Monnier, L., Colette, C., & Owens, D. R. (2021) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(21)00178-4 · Cited by 5
Inhaled Insulin Decoded: Dispelling Myths and Presenting Clinical Evidence
Kesavadev, J., Thacker, H. P., Deshpande, N., Asirvatham, A. J., Saboo, B., Kalra, P., Shaikh, S. S., Joshi, A. S., Chawla, M. S., Agarwal, S., et al. (2025) · Cureus · doi:10.7759/cureus.100247 · Cited by 3
“The study concluded that inhaled Technosphere®insulin was non-inferior to aspart in reducing HbA1c, with the added benefit of less hypoglycemia, but with a higher incidence of cough [39].”
Overcoming Therapeutic Inertia with Inhaled Insulin Therapy
Blevins, T., & Edelman, S. V. (2026) · Diabetes Technology & Therapeutics · doi:10.1177/15209156251403562 · Cited by 3
Impact of Inhaled Insulin Therapy on Hypoglycemia
Levy, C. J., & Seaquist, E. R. (2026) · Diabetes Technology & Therapeutics · doi:10.1177/15209156251381294 · Cited by 3
Dosing Afrezza: It’s Not that Complicated
Edelman, S. V., Blevins, T., Parkin, C. G., & Hirsch, I. B. (2026) · Diabetes Technology & Therapeutics · doi:10.1177/15209156251403580 · Cited by 3
Unmet Needs in Insulin-Treated Diabetes Management
Hirsch, I. B., & Parkin, C. G. (2026) · Diabetes Technology & Therapeutics · doi:10.1177/15209156251396121 · Cited by 3
Use of Inhaled Insulin with Automated Insulin Delivery Systems
Cengiz, E., & Beck, R. W. (2026) · Diabetes Technology & Therapeutics · doi:10.1177/15209156251407710 · Cited by 3
Ray, S. D., He, L. L., Rottersmann, S., Hand, C., Leo, M. D., Chunilall, A., Gray, I. G., Siu, N. T., Jong, S., Sirois, N., et al. (2026) · Diabetology · doi:10.3390/diabetology7090176 · Cited by 3
Technosphere Insulin–Induced Pulmonary Infiltrate
Parthvi, R., & Mehra, S. (2020) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000001154 · Cited by 3
Is There a Place for Inhaled Insulin in the Era of Automated Insulin Delivery?
Bai, Z., & Chow, E. (2025) · Diabetes Care · doi:10.2337/dci24-0093 · Cited by 3
Is inhaled insulin as effective as SC insulin in the management of diabetes mellitus?
Ehlbeck, K., & Moonesinghe, K. (2020) · Evidence-Based Practice · doi:10.1097/ebp.0000000000000624 · Cited by 2
“compared 24 weeks of prandial Technosphere inhaled insulin plus basal insulin (n5174) with SC aspart insulin plus basal insulin (n5171) to assess HbA1c change from baseline in uncontrolled type 1 diabetes.(2) Comparison”
MethodBell, D. S. H., & Gonçalves, E. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00809-x · Cited by 2
Treatment Approaches and Challenges
Malboosbaf, R., & Hatami, N. (2023) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9789815196535123010005 · Cited by 2
Prandial Insulins: A Person-Centered Choice
Attri, B., Nagendra, L., Dutta, D., Shetty, S., Shaikh, S. S., Kalra, S., & Bhattacharya, S. (2024) · Current Diabetes Reports · doi:10.1007/s11892-024-01540-8 · Cited by 2
“Interestingly, a few studies have shown less weight gain with Afrezza® compared to rapid analogs [114, 116].”
The Role of Inhaled Insulin in the Management of Type 2 Diabetes
Nuffer, W. A., & Trujillo, J. M. (2016) · Pharmacology & Pharmacy · doi:10.4236/pp.2016.74021 · Cited by 2
“Two were performed in patients with T1D (Studies 009 and 171) [23] [24] and two in patients with T2D (Studies 102 and 175) [25] [26].”
BackgroundCogle, S. V., & Hutchison, A. M. (2020) · Physician Assistant Clinics · doi:10.1016/j.cpha.2019.11.006 · Cited by 2
Estrategia terapéutica en el paciente diabético (III). Insulinoterapia
Ocaña, P. G., Cobos-Palacios, L., Muriel, C. C., & Jansen‐Chaparro, S. (2020) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/j.med.2020.09.021 · Cited by 2
Insulin delivery devices for diabetes mellitus from open-loop to closed-loop
Lian, D. (2021) · AIP conference proceedings · doi:10.1063/5.0049209 · Cited by 2
Hood, K. K., & Polonsky, W. H. (2026) · Diabetes Technology & Therapeutics · doi:10.1177/15209156251403584 · Cited by 1
Inhaled Technosphere Insulin Reduces Postmeal Glucose Excursion in Youth Living with Type 1 Diabetes
Ekhlaspour, L., Kanapka, L., Dewan, A. K., DiMeglio, L. A., Kipnes, M. S., Wood, M. A., Haller, M. J., Mouse, T. J., Beck, R. W., & for the INHALE-1 Study Group* (2026) · Diabetes Technology & Therapeutics · doi:10.1177/15209156261432138 · Cited by 1
Self-citationSinha, R., Zaman, S. U., Mohamed, R. C., Singh, A., Saxena, D., & Pati, A. K. (2026) · Clinical Therapeutics · doi:10.1016/j.clinthera.2026.04.020 · Cited by 1
Zelinska, N. (2020) · Ukrainian Journal of Pediatric Endocrinology · doi:10.30978/ujpe2020-4-39 · Cited by 1
Au-delà des insulines actuelles : des réalisations prometteuses et quelques désillusions
Monnier, L., Colette, C., Azrak, A. E., Essekat, N., & Rochd, D. (2022) · Médecine des Maladies Métaboliques · doi:10.1016/j.mmm.2022.12.002 · Cited by 2
Clinical Use of New Insulins and New Insulin Delivery Systems
Lim, T., & Ko, S. (2015) · Journal of Korean Diabetes · doi:10.4093/jkd.2015.16.4.242
Barag, S., Meshefedjian, T., Diep, K., & Andrew Wilson, D. O. (2018) · Integrative Obesity and Diabetes · doi:10.15761/iod.1000203
Coutant, R., Tubiana‐Rufi, N., Leroy, C., Lefebvre, C., Gueorguieva, I., Cartigny, M., Lablanche, S., & Benhamou, P. (2018) · Elsevier eBooks · doi:10.1016/b978-2-294-74942-1.00012-4
Diabetes type 1 and type 2—Insulin delivery systems
Wong, E., Vadlapatla, R., & Morello, C. M. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-819838-4.00017-1
Metadata
- Authors
- Bode, B. W., McGill, J. B., Lorber, D. L., Gross, J. L., Chang, P.-C., Bregman, D. B., & for the Affinity 1 Study Group
- Affiliations
- Atlanta Diabetes Associates (US)
- Washington University in St. Louis (US)
- NewYork–Presbyterian Hospital (US)
- Centro de Pesquisas em Diabetes Ltda., Porto Alegre, Brazil
- MannKind Corporation (United States) (US)
- Albert Einstein College of Medicine (US)
- Corresponding author
- Bode, Bruce W.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2015-07-15
- Volume
- 38
- Issue
- 12
- Pages
- 2266-2273
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2102067048
- Cited by
- 114
- References
- 24
- Citations by year
- 2026: 19 · 2025: 11 · 2024: 7 · 2023: 9 · 2022: 9 · 2021: 9 · 2020: 15 · 2019: 5 · 2018: 11 · 2017: 7 · 2016: 10 · 2015: 2
- FWCI
- 8.69
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Funders
- MannKind Corporation
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
- Keywords
- Technosphere insulin, inhaled insulin, insulin aspart, type 1 diabetes, prandial insulin, basal insulin, glycemic control, HbA1c, hypoglycemia, weight gain, cough, non-inferiority
- MeSH terms
- Administration, Inhalation, Adolescent, Adult, Aged, Diabetes Mellitus, Type 1, Female, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Injections, Subcutaneous, Male, Microspheres, Middle Aged, Powders, Young Adult, Insulin Aspart, Insulin, Regular, Human
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.